Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug

Wiley - Tập 13 Số 1 - Trang 57-78 - 2007
Tim De Smedt1, Robrecht Raedt1, Kristl Vonck1, Paul Boon1
1Laboratory for Clinical and Experimental Neurophysiology ‐ Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium

Tóm tắt

ABSTRACTThe objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add‐on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad‐spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long‐term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.

Từ khóa


Tài liệu tham khảo

10.1016/S1059-1311(02)00274-1

10.1016/j.seizure.2004.12.006

Arroyo S, 2003, Safety profile of levetiracetam, Epileptic Disord, 5, 57

Arroyo S, 2004, The IUPHAR Compendium of Basic Principles For Pharmacological Research in Humans, 165

10.1111/j.1600-0404.2006.00657.x

Ben‐Menachem E, 2003, Preliminary efficacy of levetiracetam in monotherapy, Epileptic Disord, 5, 51

10.1111/j.1528-1157.2000.tb04605.x

10.1016/S0920-1211(02)00247-4

Ben‐MenachemE BrodieMJandPerucca E on behalf of the N01061 Study Group(2006)Efficacy of levetiracetam monotherapy

randomized double‐blind head‐to‐head comparison with carbamazepine‐CR in newly diagnosed epilepsy patients with partial onset or generalized tonic‐clonic seizures.Presented at the American Academy of Neurology April 2006 and discussed in EMEA procedure number EMEA/H/C/277/II/63.

10.1111/j.1528-1167.2005.00328.x

10.1053/seiz.2000.0380

10.1016/S0920-1211(01)00323-0

Buck ML, 2002, Levetiracetam for the treatment of partial seizures, Pediatric Pharmacoth, 8, 1

10.1212/WNL.55.2.236

10.1016/S1059-1311(02)00273-X

Covanis A, 2003, Levetiracetam monotherapy in generalized epilepsy and photosensitivity, Epilepsia, 44, 80

10.1136/jnnp.2005.064626

Edwards KR, 2004, Levetiracetam levels in human cerebrospinal fluid: A controlled, dose ranging pharmacokinetic study, Neurology, 62, 118

10.1016/j.yebeh.2003.09.007

10.1056/NEJM198707163170304

10.1111/j.1528-1167.2001.00009.x

10.1016/S0920-1211(01)00202-9

10.1111/j.1600-0404.2006.00647.x

10.1046/j.1528-1157.2002.13101.x

10.1212/01.wnl.0000217916.00225.3a

10.1016/S0920-1211(00)00158-3

10.1111/j.1528-1167.2005.00329.x

10.1111/j.1528-1167.2001.00008.x

10.1212/WNL.67.12_suppl_4.S56

Hirsch E, 2002, Open study on the efficacy of levetiracetam monotherapy in idiopathic generalized epilepsies, Epilepsia, 43, 62

10.1212/01.wnl.0000244491.48937.55

10.1111/j.1528-1167.2005.54804.x

10.1016/S0920-1211(96)00031-9

10.1016/j.yebeh.2004.07.009

10.1212/WNL.56.12.1772

10.1016/j.seizure.2005.12.004

10.1111/j.0013-9580.2003.00403.x

10.1016/S1525-5050(03)00122-7

10.1097/00007691-200312000-00007

10.2165/00003088-200241080-00002

10.1111/j.1468-1331.2006.01381.x

10.1016/S0920-1211(03)00080-9

10.1212/01.WNL.0000078031.32904.0D

10.1016/S1059-1311(03)00111-0

10.1097/01.wnf.0000159956.87511.67

10.1016/S0163-7258(99)00052-2

10.2165/00003088-200443110-00002

10.1046/j.1528-1157.2001.41300.x

Perucca E, 2000, Levetiracetam: Absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs), Epilepsia, 41, 150

10.1046/j.1528-1157.2001.042suppl.3031.x

10.1016/S0920-1211(02)00250-4

10.1111/j.1528-1167.2001.00007.x

10.1111/j.1528-1167.2006.00586.x

10.1016/j.clinthera.2006.05.004

10.1046/j.1528-1157.2002.57701.x

Resor SR, 2002, Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy. Presented at the 54th Annual Meeting of the American Academy of Neurology In: Grünewald R (2005) Levetiracetam in the treatment of idiopathic generalized epilepsies, Epilepsia, 46, 154

10.1016/j.seizure.2006.05.012

Rosenfeld WE, 2006, Efficacy and safety of levetiracetam as adjunctive treatment in adult and pediatric subjects suffering from idiopathic generalized epilepsy with primary generalized tonic‐clonic seizures, Neurology, 66, A40

10.1111/j.1528-1157.2000.tb00323.x

Shorvon SD, 2002, A new antiepileptic drug, JNNP, 72, 426

10.1016/S0920-1211(01)00309-6

10.1212/WNL.57.5.858

10.1016/S0890-6238(02)00020-5

10.1046/j.1528-1157.2003.60702.x

10.1111/j.1528-1167.2006.00668.x

10.1016/j.reprotox.2004.12.001

Ten Berg K, 2006, Outcomes of human pregnancies after levetiracetam exposure, Birth Defects Res Part A Clin Mol Teratol, 76, 318

10.1053/seiz.2001.0497

Verdru P, 2005, Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures, Epilepsia, 46, 56

Weintraub D, 2006, Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy, Epilepsy Behav

10.1345/aph.1A032

10.1212/01.WNL.0000091865.46063.67

Thông tin
Thông tin xuất bản

Wiley

Tập 13 Số 1

57-78

Thông tin tác giả